1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Reflux Esophagitis Disease Overview

3. Reflux Esophagitis R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Reflux Esophagitis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Reflux Esophagitis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Reflux Esophagitis companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Reflux Esophagitis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services

Companies mentioned
CalyGene Biotechnology Inc, Cancer Advances Inc, Cinclus Pharma AG, CJ HealthCare, Daewoong Pharmaceutical Co , Eisai Co Ltd, Handa Pharmaceuticals LLC, Il-Yang Pharm.Co.,Ltd, Ironwood Pharmaceuticals, Jeil Pharmaceutical Co Ltd, Jiangsu Aosaikang Pharmaceutical, RaQualia Pharma Inc, Renexxion LLC , Takeda Pharmaceutical Co, Trio Medicines Ltd, Yooyoung Pharm Co Ltd, Yuyu Pharma Inc